Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Pfizer lifted its 2026 revenue forecast by $500 million at the midpoint.
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...
Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.
Pfizer (NYSE:PFE) increased the lower end of its full-year revenue guidance after reporting second-quarter 2026 results that exceeded Wall Street expectations, supported by robust sales of its blood thinner Eliquis. The pharmaceutical company also reaffirmed its earnings outlook for the year, while its shares moved higher in U.
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer stock inched higher early Tuesday on a solid second-quarter report that included a sales guidance boost.
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.6% year on year to $15.03 billion. The company expects the full year’s revenue to be around $61.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 12.9% above analysts’ consensus estimates.
Rising sales of drugs for cancer and heart disease helped offset steep declines for Pfizer’s Covid-19 products.
Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as an oral therapy for this autoimmune skin disease. For investors watching Pfizer, this update highlights an area of its late stage pipeline that sits outside its COVID and oncology businesses. Nonsegmental vitiligo is a chronic condition with limited systemic treatment options, so additional clinical data around efficacy and safety is...
Pfizer faces $17 billion patent cliff as investors brace for earnings
Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
The drugmaker posted adjusted earnings of 77 cents per share and now expects full-year revenue of $60.5 billion to $62.5 billion
Stock futures were rising on Tuesday, putting the on the brink of a record high as tech extended its recent rebound. Palantir was the S&P 500’s best performer ahead of the opening bell, surging 16% after the data analytics software developer reported strong second-quarter earnings. CEO Alex Karp described the quarter as “otherworldly,” as U.S. commercial revenue rose 149% from a year ago.
Aug 4 () - Pfizer on Tuesday slightly raised the lower end of its full-year revenue forecast after beating Wall Street estimates for second-quarter profit, driven by strong demand for blood thinner Eliquis. Pfizer is banking on newer medicines to offset fading COVID revenue and reduce reliance on aging blockbuster drugs, while investors look for signs that its $10 billion purchase of Metsera can help establish a meaningful presence in the fast-growing obesity market.
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
The stock's yield is more than six times the S&P 500 average.
J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.
Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev’s chief...
Earnings continue to be the market's engine, and a series of results this week from Palantir, SpaceX, and AMD are set to rev up stocks again.